Trial Profile
Long-Term Immunity and Safety With or Without a Booster Dose Following Primary Vaccination With the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population in a JEV-Endemic Country. Open-Label, Randomized, Phase 3 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs IC 51 (Primary)
- Indications Japanese encephalitis
- Focus Pharmacodynamics
- Sponsors Valneva
- 15 Jun 2018 Results published in the Pediatric Infectious Disease Journal
- 26 Apr 2017 New trial record